CNS Pharmaceuticals, Inc.

CNSP

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001729427

None

No letter

4 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $8.6M
Warnings	thin data not computable: dilution, degenerate inputs, distress, fortress balance sheet
Inputs computable	4 of 14
Graded from	filings received through Apr 30, 2026 194 days before the rescan; latest periodic filing 10-Q received Aug 12, 2026
Last close	$4.39 2026-11-02; market equity $6.4M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 31, 2026

"we," "us," or "our") is a biotechnology company focused on developing innovative therapies for serious diseases in neurology and oncology. Together, these therapeutic areas represent hundreds of billions of dollars in annual global pharmaceutical spending, encompass some of the most prevalent and difficult to treat diseases affecting humanity, and are characterized by significant unmet medical need. Significant progress has been made in the biological and molecular understanding of these diseases, enabling a shift to high-value disease-modifying therapies and precision medicine approaches.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 18.0						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing					
Accruals ratio	(23.5%)	(6.6%)	18.0	800	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 80.0					
Twelve-month failure probability	not computable	0.08%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	(46.16)	(0.35)	87.8	745	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
interest expense must exceed $100,000					
Current ratio	1.98x	2.95x	72.2	826	2025-12-31
Growth and financing, sleeve percentile 73.4					
Revenue growth, three-year compound	not computable	10.1%			
four annual observations are required; found 0					
Free cash flow growth, three-year compound	not computable	11.0%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
one or more required annual facts are missing					
Asset growth, three years	(12.9%)	2.2%	73.4	694	2025-12-31
Net share issuance, one year	not computable	2.5%			
prior share count is 27 days earlier					

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	4 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-02 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(31.2%)	(1.9%)	29
Distance from 52-week high	(49.7%)	(27.5%)	29
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(240.2%)	(1.0%)	3
Book value to price	3.16	0.27	98
Sales to price	not computable	0.29	
Composite equity issuance, five years	1,085.9%	20.8%	99
Relative strength against the sector, log excess return	(0.54)	(0.19)	29

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$20.0M
Operating cash flow, four quarters	-$13.4M
Months of runway	17.9
Days since last periodic filing	90 (10-Q received Aug 12, 2026)
Median daily dollar volume, 63 sessions	$23,984

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$15.9M	2025-12-31	2026-03-31	10-K	26-002550
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$13.8M	2025-12-31	2026-03-31	10-K	26-002550
3	assets	us-gaap:Assets	$8.6M	2025-12-31	2026-03-31	10-K	26-002550
4	assets	us-gaap:Assets	$8.7M	2024-12-31	2026-03-31	10-K	26-002550
5	current assets	us-gaap:AssetsCurrent	$8.1M	2025-12-31	2026-03-31	10-K	26-002550
6	current liabilities	us-gaap:LiabilitiesCurrent	$4.1M	2025-12-31	2026-03-31	10-K	26-002550
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$100.3M	2025-12-31	2026-03-31	10-K	26-002550
8	operating income	us-gaap:OperatingIncomeLoss	-$16.0M	2025-12-31	2026-03-31	10-K	26-002550
9	book equity	us-gaap:StockholdersEquity	$4.5M	2025-12-31	2026-03-31	10-K	26-002550
10	liabilities	us-gaap:Liabilities	$4.1M	2025-12-31	2026-03-31	10-K	26-002550
11	operating income	us-gaap:OperatingIncomeLoss	-$18.9M	2023-12-31	2025-03-31	10-K	25-002139
12	interest expense	us-gaap:InterestExpense	$13,805	2023-12-31	2024-04-01	10-K	24-002032
13	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$18,175	2025-12-31	2026-03-31	10-K	26-002550
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$17.1M	2024-12-31	2026-03-31	10-K	26-002550
15	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$4,188	2024-12-31	2026-03-31	10-K	26-002550
16	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$14.1M	2023-12-31	2025-03-31	10-K	25-002139
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$3,901	2023-12-31	2025-03-31	10-K	25-002139
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$10.6M	2022-12-31	2024-04-01	10-K	24-002032
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$4,422	2022-12-31	2024-04-01	10-K	24-002032
20	assets	us-gaap:Assets	$1.7M	2023-12-31	2025-03-31	10-K	25-002139
21	assets	us-gaap:Assets	$13.1M	2022-12-31	2024-04-01	10-K	24-002032
22	shares outstanding	dei:EntityCommonStockSharesOutstanding	811,449	2026-04-27	2026-04-30	10-K/A	26-003374
23	shares outstanding	dei:EntityCommonStockSharesOutstanding	811,449	2026-03-31	2026-03-31	10-K	26-002550

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.